Digestery
Longevity supplements › Fisetin and Aging › Studies

Animal study

In mice with kidney damage from a cancer drug, fisetin and ABT-263 reduced scarring

Li and colleagues · JCI insight · 2023

Original title: Tubular cell senescence promotes maladaptive kidney repair and chronic kidney disease after cisplatin nephrotoxicity.

Under review. A person has not yet checked this summary against the paper. It is written from the PubMed abstract. Until a person checks it, search engines are asked not to list this page.

What the study found

Points to benefit

Clearing worn-out kidney cells with ABT-263 and fisetin reduced scarring and improved kidney repair and function in mice. Abstract gives no numbers.

The study at a glance

Type of study
Animal study
Who or what was studied
mice with kidney damage from the cancer drug cisplatin
What was tested
Two senolytic drugs, ABT-263 and fisetin, given to mice after cisplatin
What it measured
Several kinds of outcomes
Who has a stake
No stake declared
No conflict of interest exists, per the authors.
Journal
JCI insight, 2023
Source
PubMed record 36917180. This page is based on the abstract only.

How much this study counts

  • –Done in animals. Results in animals often do not carry over to people.
  • ✓No competing interests declared.
  • •Summarized from the PubMed abstract only. The full paper may hold details the abstract leaves out.

✓ Strength– Limit• Note

These points come from fixed rules about the type of study, its size and length, what it measured, and who has a stake. Every study on Digestery gets the same rules.

Where this study sits

Each dot is one on-topic paper on this question. Steps near the top answer the question more directly.

↑ Stronger evidence

  1. Trials in people: aging and age-related decline

    0

    Not done yet. This is the step that would answer the question.

  2. Trials in people: other measures

    0

    None among the papers we read.

  3. Trials in people: lab tests or safety

    0

    None among the papers we read.

  4. Population studies

    1

    1 benefit

  5. Blood levels and genes

    0

    None among the papers we read.

  6. Animals

    5

    5 benefit

    ↑ This study is the ringed dot

  7. Cells in a dish

    1

    1 mixed

↓ Weaker evidence

  • Points to benefit
  • Mixed
  • No difference
  • No direction
  • Points to harm

How it fits with the other research

The short answer to “Does fisetin slow aging?”

Not shown in people.

Confidence: very low. Based on 12 on-topic papers.

Read the full answer

Of the other 4 papers on the same step: 4 benefit. This one found benefit. It agrees with most of them.

  • Quoted in “What we found”: In mice with obesity, lupus, kidney damage or muscular dystrophy, fisetin lowered worn-out cells and improved sugar handling, behavior, kidney repair or muscle.
  • Part of the finding “In sick mice, fisetin cleared worn-out cells”.

Other papers on the same step

See all 12 studies on this question

How this page was made

Label

First read of the abstract
Claude Sonnet
Independent second read
Claude Haiku
Differences settled
The two reads agreed on every checked field. Claude Opus 5.5.
Headline
Claude Sonnet, from the checked study record. A script checked its numbers and wording.
Numbers
Checked against the abstract by a script
“How much this study counts”
Fixed rules, the same for every study
Source check by a person
Not yet. Required before search engines may list this page.

Spot an error? Email a flag with a link to your source, or use the form on the question page.